Key points from article :
Unity Biotechnology’s technology jump starts senescent cells into dividing again.
Company has raised $116 million.
Human trials planned in the next 12-18 months will focus on eye diseases
Ned David: “we do expect people to live free of a variety of chronic diseases.”
